Home blood pressure monitoring (HBPM) is increasingly being recognized as an accurate adjunct to clinic blood pressure measurement for the diagnosis and management of hypertension. We discussed the HOPE Asia Network’s recently published consensus recommendations on HBPM with lead author, Prof. Sungha Park.
Click here to view the interview video with one of the authors - Professor Sungha Park
In an effort to better understand hypertension subtypes – including morning and white-coat hypertension – in Asian patients, the HOPE Asia Network has initiated the Asia BP@Home study across 12 countries and regions. We discussed the study’s design and objectives with lead investigator, Prof. Kazuomi Kario.
Click here to view the interview video with lead investigator - Professor Kazuomi Kario
Data presented at the 13th APCH, and recently published in the Journal of Clinical Hypertension, highlighted the current challenges of hypertension management in Asia and how home blood pressure monitoring may improve cardiovascular outcomes. We discussed the paper with lead author, Prof. Yook-Chin Chia.
Results from the ASCOT-LLA study suggest that patient reports of muscle-related adverse events were more common when patients knew they were being treated with a statin. We discussed this phenomenon, known as the ‘nocebo effect’, with senior investigator, Prof. Peter Sever.
Physicians’ practice patterns in managing hypertension, and their awareness of blood pressure variability, were reported in a recent study in Singapore. We discussed some of the clinical practice gaps identified by this study with author, A/Prof. Teo Boon Wee.
In patients with rheumatoid arthritis (RA), temporary cessation of methotrexate (MTX) treatment for 2 weeks following influenza vaccination appears to improve the immunogenicity of the vaccine without increasing RA disease activity, according to a study.
Acute coronary syndrome (ACS) patients with diabetes mellitus, as well as high-risk nondiabetic patients, appear to obtain significant cardioprotection from the addition of ezetimibe to simvastatin, and this benefit is achieved without compromising safety, according to an exploratory analysis of data from IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial).
Overweight or obese patients taking lorcaserin as an appetite suppressant may have the added benefit of a reduced risk of incident diabetes, according to results of the CAMELLIA-TIMI 61* trial presented at EASD 2018.